All In Biotech

Drug Trial Radar · NCT07174726

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 10, 2025

Primary completion

Dec 31, 2029

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Beacon TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Conditions

  • X-Linked Retinitis Pigmentosa (XLRP)

Interventions

  • Adeno-associated virus vector expressing a human RPGR geneBiological

    Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and percentage of participants experiencing Grade 3 or higher ocular or non-ocular treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), at Month 12Time frame: Day 0 - Month 12

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida Jacksonville Ophthalmology

    Jacksonville, Florida

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Duke Eye Center

    Durham, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • OHSU Casey Eye Institute

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.